Payment overview · 2025
General Payments
$451.51
28 reported records · 5 companies
Healthcare provider profile · identity verified
Fernando Garcia, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HARLINGEN, TX · NPI 1164539508
Verified facts
What the public records show
CMS Open Payments records show Fernando Garcia, M.D. received $451.51 in general payments during 2025 across 28 reported records.
ViiV Healthcare Company accounted for 43.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Dovato.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Descovy by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Isentress by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ozempic by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $194.18 | 43.0% | 11 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $150.06 | 33.2% | 12 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $47.80 | 10.6% | 3 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $39.02 | 8.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.45 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $451.51 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $134.81 | 6 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $59.37 | 5 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $50.03 | 5 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $47.80 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 70 | exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 69 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
70 | 11 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
69 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 271 | 57 |
| Atorvastatin Calcium | Atorvastatin Calcium | 265 | 63 |
| Lisinopril | Lisinopril | 174 | 39 |
| Metformin Hcl | Metformin Hcl | 145 | 22 |
| Losartan Potassium | Losartan Potassium | 143 | 39 |
| Gabapentin | Gabapentin | 135 | 21 |
| Levothyroxine Sodium | Levothyroxine Sodium | 110 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 109 | 59 |
| Trazodone Hcl | Trazodone Hcl | 109 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 33 |
| Mirtazapine | Mirtazapine | 94 | 13 |
| Amlodipine Besylate | Amlodipine Besylate | 85 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 22 |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 81 | suppressed |
| Jardiance | Empagliflozin | 80 | 17 |
| Eliquis | Apixaban | 77 | 11 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 70 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 70 | 13 |
| Dovato | Dolutegravir Sodium/Lamivudine | 69 | 11 |
| Baclofen | Baclofen | 68 | 13 |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 68 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 68 | 14 |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 62 | suppressed |
| Levofloxacin | Levofloxacin | 57 | 55 |
| Memantine Hcl | Memantine Hcl | 57 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 18 |
| Famotidine | Famotidine | 48 | 27 |
| Donepezil Hcl | Donepezil Hcl | 46 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 46 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 11 |
| Levetiracetam | Levetiracetam | 46 | 11 |
| Pregabalin | Pregabalin | 46 | suppressed |
| Carvedilol | Carvedilol | 45 | 12 |
| Simvastatin | Simvastatin | 45 | 13 |
| Glipizide | Glipizide | 42 | suppressed |
| Lactulose | Lactulose | 42 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 41 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 39 | suppressed |
| Sucralfate | Sucralfate | 39 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Abacavir-Lamivudine | Abacavir Sulfate/Lamivudine | 36 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 36 | 11 |
| Divalproex Sodium | Divalproex Sodium | 35 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | 18 |
| Budesonide | Budesonide | 34 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 34 | suppressed |
| Ritonavir | Ritonavir | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Potassium Chloride | Potassium Chloride | 29 | 11 |
| Spironolactone | Spironolactone | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Paliperidone Er | Paliperidone | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Mupirocin | Mupirocin | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 23 | suppressed |
| Etravirine | Etravirine | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Prezista | Darunavir | 23 | suppressed |
| Tivicay | Dolutegravir Sodium | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | 11 |
| Dapsone | Dapsone | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Omeprazole | Omeprazole | 21 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Allopurinol | Allopurinol | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 19 | suppressed |
| Isentress | Raltegravir Potassium | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 15 |
| Juluca | Dolutegravir/Rilpivirine | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Entacapone | Entacapone | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Permethrin | Permethrin | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Pyrimethamine | Pyrimethamine | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Complera | Emtricita/Rilpivirine/Tenof Df | 12 | suppressed |
| Darunavir | Darunavir | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Evotaz | Atazanavir Sulfate/Cobicistat | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Egrifta Sv | Tesamorelin Acetate | 11 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 11 | suppressed |
| Klayesta | Nystatin | 11 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 11 | suppressed |
| Neupro | Rotigotine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $451.51 · 28 records | ViiV Healthcare Company | Biktarvy, CABENUVA, DOVATO, PIFELTRO | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error